Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

T3D Therapeutics

T3D Therapeutics
2013 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Series B LATEST DEAL TYPE
$15M LATEST DEAL AMOUNT
1 INVESTORS
Description

Developer of a novel drug therapy intended to stop or reverse the course of Alzheimer's disease. The company's drug is an orally-delivered once-a-day medicine that targets both the brain 'starvation' and neurodegeneration of Alzheimer's disease and helps in treating multiple manifestations of the disease, providing Alzheimer patients with a drug to potentially improve multiple defects and improve memory, motor function and cognition.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
  • 68 T.W. Alexander Drive
  • P.O. Box 13628
  • Research Triangle Park, NC 27709
  • United States

+1 (919) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore T3D Therapeutics’s full profile, request a free trial.

T3D Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Later Stage VC (Series B) 04-Nov-2019 $15M 000.00 Completed Generating Revenue
8. Grant 20-May-2019 000 000.00 Completed Clinical Trials - Phase 2
7. Early Stage VC (Series B) 10-Mar-2018 000 000.00 0000 Completed Clinical Trials - Phase 2
6. Early Stage VC (Series A3) 11-Mar-2016 00.000 00.000 0000 Completed Clinical Trials - Phase 2
5. Grant 24-Mar-2015 00.000 00.00 Completed Clinical Trials - Phase 2
4. Debt - General 31-Jul-2014 00000 00.00 Completed Startup
3. Early Stage VC (Series A2) 14-Mar-2014 00000 00.000 00.000 Completed Startup
2. Debt - General 24-Jun-2013 $50K $487K Completed Startup
1. Angel (individual) 20-Jun-2013 $437K $437K 00.000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

T3D Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A3 0,000,000 00.000000 00 00 00 00 00 0.000
Series A2 000,000 00.000000 00 00.0 00.0 00 00.0 0.000
Series A1 404,628 $0.001000 6% $1.08 $1.08 1x $1.08 7.26%
To view this company’s complete Cap Table, request access »

T3D Therapeutics Competitors (29)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Yumanity Therapeutics Venture Capital-Backed Cambridge, MA 00 000.00 0000000000 0 000.00
0000000 Venture Capital-Backed Framingham, MA 0 0000 00000000
00000 000000000000 Formerly VC-backed Cambridge, MA 000.00 000000&0 000.00
00000 Venture Capital-Backed Pittsburgh, PA 00 000.00 0000000000 0 000.00
000000000 Formerly VC-backed South San Francisco, CA 00 00000 00000000 00000
To view this company’s complete list of competitors, request access »

T3D Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
National Institute On Aging Government 000 0000 000000 0

T3D Therapeutics Executive Team (3)

Name Title Board
Seat
Contact
Info
John Didsbury Ph.D Founder, Chairman of the Board, President & Chief Executive Officer
Stanley Chamberlain Ph.D Chief Scientific Officer
Warren Strittmatter MD Chief Medical Officer

T3D Therapeutics Board Members (5)

Name Representing Role Since Contact
Info
Barry Buzogany JD T3D Therapeutics Board Member 000 0000
Charles Lineberry Ph.D T3D Therapeutics Board Member 000 0000
John Didsbury Ph.D T3D Therapeutics Founder, Chairman of the Board, President & Chief Executive Officer 000 0000
John Golden Self Board Member 000 0000
Thomas Mendell Self Board Member 000 0000